(BUSINESS WIRE)–Jan. 14, 2015– BioLineRx Ltd. (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that patient enrollment has been completed in Bellerophon’s PRESERVATION I pivotal CE Mark registration trial of BL-1040, currently named Bioabsorbable Cardiac Matrix (BCM), a novel resorbable polymer solution for the prevention of cardiac remodeling following an acute myocardial infarction (AMI). “We are very excited with… Read more »
Shares of Biolinerx closed yesterday at $2.03 . BLRX has a 1-year high of $3.12 and a 1-year low of $1.20. The stock’s 50-day moving average is $1.64 and it’s 200-day moving average is $1.64.
On the ratings front, Biolinerx has been the subject of a number of recent research reports. In a report published on January 7, analyst Jason Kolbert from Maxim Group reiterated a Buy rating on BLRX, with a price target of $8, which represents a potential upside of 294.1% from where the stock is currently trading. Separately, on January 6, Roth Capital`s Joseph Pantginis maintained a Buy rating on Biolinerx shares and has a price target of $10.50.
Bioline Rx Ltd is a clinical stage biopharmaceutical development company engaged in identifying, in-licensing & developing therapeutic compounds in areas of central nervous system, oncology, cardiovascular, & infectious diseases, among others.